Telomerase activity and telomere length in mononuclear cells proliferation of lymphoid or myeloid precursors with arrested (MNCs) and granulocytes from peripheral blood (PB) and bone maturation.
14
measurements show significant changes in pediatric patients cyclophosphamide 2.2 g/m 2 ). Hodgkin's disease patients were treated according to the CCG protocol for Hodgkin's lymundergoing chemotherapy; (2) whether telomerase activity and TRF measurements in BM and PB samples in acute leukephoma with COPP/ABV-hybrid (cyclophosphamide 600 mg/m 2 , vincristine 1.4 mg/m 2 , procarbazine 100 mg/m 2 , mia differ from childhood ST and healthy donor specimens; and (3) whether serial measurements of telomerase activity prednisone 40 mg/m 2 , doxorubicin 35 mg/m 2 , vinblastine 6 mg/m 2 , and bleomycin 10 mg/m 2 ). 41, 42 The patient with may serve as a molecular marker of residual disease. Our results illustrate that telomerase is consistently and highly Wilms' tumor was treated according to the NWTS protocol (National Wilms' Tumor study V) with cyclophosphamide upregulated in BM and PB specimens in leukemia, decreases after induction therapy, and correlates with remission. BM 73.5 mg/kg, doxorubicin 1.5 mg/kg, etoposide 3.3 mg/kg and vincristine 0.05 mg/kg. The ependymoma patient received the specimens in leukemia showed increased telomerase activity, most likely due to the higher leukemic burden compared to CCG 9921 protocol for malignant brain tumors with cyclophosphamide 110 mg/kg, cisplatin 3.5 mg/kg, vincristine PB specimens. TRF measurements allowed us to detect leukemic cells at diagnosis, to monitor the disappearance of the 0.05 mg/kg and etoposide 7.5 mg/kg. The CNS germ cell tumor patient was treated according to the 2nd International malignant clone in remission and to demonstrate progressive shortening of telomeres after chemotherapy treatment. These CNS Germ Cell Tumor Protocol (cyclophosphamide 4 g/m 2 , cisplatin 105 mg/m 2 , etoposide 450 mg/m 2 , bleomycin results suggest that telomerase activity and TRF length analysis may be useful for diagnostic and remission assessment in leu-15 mg/m 2 ) and the patient with the localized malignant germ cell tumor of the ovary was treated according to CCG 8891 kemia as well as for evaluating potential complications after repeated cycles of chemotherapy treatment.
(cisplatin 100 mg/m 2 , bleomycin 15 mg/m 2 and etoposide 500 mg/m 2 ). The hepatoblastoma patient received chemotherapy with cisplatin 3 mg/kg and doxorubicin 0.6 mg/kg. In two solid tumor patients, high-dose chemotherapy with stem Materials and methods cell support was performed. The metastatic Ewing's sarcoma patient underwent autologous bone marrow transplantation
Patients and cell specimens (ABMT) following high-dose cyclophosphamide 3 g/m 2 , melphalan 200 mg/m 2 , etoposide 800 mg/m 2 and carboplatin Twenty-five pediatric patients were studied. Peripheral blood (PB, n = 65) and bone marrow (BM, n = 31) specimens were 1200 mg/m 2 , whereas the refractory stage IV Wilms' tumor patient received PB support (peripheral blood stem cell transcollected from patients with acute leukemia (acute lymphocytic leukemia (ALL) n = 15 and acute myeloid leukemia plantation (PBSCT)) following thiotepa 750 mg/m 2 and carboplatin 1200 mg/m 2 . (AML), n = 1) and from solid tumors (ST, n = 9) at diagnosis, during and after chemotherapy. From each PB and BM speci-
The number of chemotherapy cycles given in ST and acute leukemia patients was counted. Although in childhood ALL, men, MNCs and granulocytes were density separated and analyzed separately. In four pediatric ST patients (two sarthe treatment according to BFM protocol consists of continuous chemotherapy, we defined induction, consolidation, coma, one Wilms', one Hodgkin's disease), tissue specimens were available. From healthy donors, cord blood (CB, n = 8), interim maintenance, delayed reinduction and delayed intensification as one cycle each, with a total of five cycles during PB (n = 37) and BM (n = 8) specimens were used as controls. A total of 250 specimens were analyzed. Specimens were colthe first 6 months of treatment. lected between April 1996 and April 1997, and patients were followed clinically. Diagnostic and follow-up specimens were obtained in 23/25 patients. In two, only diagnostic tissue, BM Cell separation procedure or PB could be obtained, and no follow-up specimens were available. The study was performed in accordance with local From each heparinized PB and BM specimen in pediatric patients, mononuclear cells (MNC) and granulocytes were institution approved regulations, and informed written consent was obtained from each patient and healthy donor. All separated on a prepared Percoll gradient (Pharmacia, Uppsala, Sweden; density = 1.04 g/ml). From a 90% stock solpatients were treated according to standard chemotherapy protocols. ALL patients were treated according to the modified ution of Percoll, diluted with 10 × PBS without Ca and Mg (Gibco, Grand Island, NY, USA), 78% and 62% Percoll sol-BFM (Berlin-Frankfurt-Mü nster) protocol. [37] [38] [39] [40] The AML patient was treated according to the Children's Cancer Group utions were prepared, using ively. PB and BM specimens were diluted 1:2 with PBS prior to the Percoll separation. The 62% Percoll was gently layered 400 mg/m 2 , dexamethasone 24 mg/m 2 , 6-thioguanine 400 mg/m 2 and age-adjusted intrathecal cytarabine. In the ST over the 78%, the diluted blood mixture over the 62%, and then centrifuged at 100 g for 30 min. Due to their different patient group, there were two sarcomas (one metastasized Ewing's sarcoma, one stage I rhabdomyosarcoma), two Hodgdensities, MNCs were collected in the top interface and granulocytes in the middle interface from each PB or BM specikin's disease (stage IA and IIB according to the Ann Arbor classification), two CNS tumors (one localized ependymoma men. From healthy donors (n = 53), heparinized CB (n = 8), PB (n = 37) and BM (n = 8) samples were obtained, and MNCs and one primary multifocal CNS germ cell tumor), one stage IV Wilms' tumor with lung metastases, one stage III hepatoblawere separated by Ficoll-Paque (Pharmacia) density gradient centrifugation (100 g for 30 min). After Percoll and Ficollstoma and one localized germ cell tumor of the ovary. The chemotherapy regimens in the sarcoma patients were given Paque separations, cells were washed twice with 0.1% BSA in PBS. Cellular viability and cell counts were assessed using according to the CCG protocol 7951 for metastatic Ewing extended by telomerase present in the extract with at least three telomeric repeats. The assay was in the linear range from Cells from a total of 250 specimens were processed as 0.001 amol (1 TPG) to 1 amol (1000 TPG) of R8. This range described previously. 6, 43 Specimens were homogenized with extended over three logs of our target protein concentration ice-cold lysis buffer (10 6 cells/100 l): 0.5% 3-(data not shown). All results were determined from at least ((3-cholamidopropyl)dimethylammonio)-1-propane-sulfonate, three to six independent TRAP assays. The specificity of the 10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1 mM EGTA, 10% gly-6 bp ladder was confirmed by the abolition of these ladders cerol, 5 mM ␤-mercaptoethanol, and 1 ng/ml leupeptine, were by heat inactivation of the protein extracts. Negative samples incubated on ice for 30 minutes, and centrifuged at 12 000 g were re-exposed for 72 h to exclude weak enzyme activity. for 30 min at 4°C. The supernatant was collected and the proSpecimens showing no telomerase were reassayed at 0.2 and tein concentration was determined by the Bradford assay (Bio-0.02 g of protein, because inhibition of telomerase activity Rad Laboratories, Richmond, CA, USA). Aliquots were diluted at high protein concentrations has been reported. Telomerase to 1 g protein/l and stored at −80°C. Alkaline phosphatase activity was defined as positive when specimens displayed activity was analyzed in each extract to measure protein stabvalues of у5 TPG. Borderline telomerase activity was defined ility and indirectly telomerase integrity, as the stability of alkawith values Ͻ5 TPG. However, since the sensitive TRAP assay line phosphatase appears to be similar to the stability of teloallows the detection of very low telomerase levels, low or bormerase. 20, 43 Telomerase activity was measured by a protocol derline telomerase activity as observed in healthy donors and recently developed, 64 which enables estimation of the level of PB specimens of solid tumor patients could be calculated in activity in a quantitative manner and includes a PCR internal TPG (given as median TPG values). control. In brief, the TRAP assay was performed as follows. Two g of protein extract were assayed in reaction tubes containing 50 l of the TRAP reaction mixture. The TS primer (5Ј-TRF assay AATCCGTCGAGCAGAGTT-3Ј) was end-labeled using T4 polynucleotide kinase (PNK) (Promega, WI, USA) and 25 
Ci
Telomere length was determined by TRF Southern blot analyof 3000 Ci/mmol ␥-32 P-ATP per 1 g of TS. T4 PNK was used sis as previously described. 5, 6, 8, 12, 19 Genomic DNA from all at 25 U per 1 g of TS and incubated at 37°C for 20 min, 250 specimens was digested with 400 l DNA extraction followed by heat inactivation at 95°C for 5 min. Each TRAP buffer (100 mM NaCl Electrophoresis of digested genomic DNA was performed in TSNT is the PCR internal control amplified by the primers TS 0.5% agarose gels in 45 mM TBE buffer (pH 8.0) for a total of and NT that gives a 36 bp product, running 14 bp below the 660-700 V/h. After electrophoresis, gels were depurinated in smallest TRAP band. This is used to monitor the PCR 0.2 N HCl, denatured in 0.5 M NAOH/1.5 M NaCl, neutralized efficiency during the PCR step of this assay. Thirty-min incuin 0.5 M Tris/1.5 M NaCl, transferred to a nylon membrane bation at room temperature (RT) for telomerase-mediated (Schleicher and Schuell, Keene, NH) using 20 × SSC and dried extension of the TS primer was allowed. The products were for 1 h at 70°C. The telomeric probe (TTAGGG) 3 (Genset, La amplified by 30 cycles at 94°C, 60°C, and 72°C for 30 s each Jolla, CA, USA) was 5Ј-end labeled with ␥-32 P-ATP using T4 and were separated by electrophoresis on 15% polyacrylampolynucleotide kinase (Boehringer Mannheim). Prehybridizide gels. The gel was dried for 1 h at 80°C and exposed to an ation and hybridization were performed at 50°C using image plate. In every gel a negative control (2 l of CHAPS 5 × Denhardt's solution, 5 × SSC/0.1 M Na 2 HPO 4 /0.01 M lysis buffer) and 0.1 amol of the quantitation standard oligonuNa 4 P 2 0 7 , and 30 g of salmon sperm DNA per ml/0.1 mM cleotide R8 (5Ј-AATCCGTCGAGCAGAGTTAG[GGTTAG] 7 -ATP. Membranes were washed in 0.5 × SSC/0.1% SDS sol-3Ј) were inc-luded. The R8 quantitation standard oligonucleution. Telomeric smears were visualized by exposing the otide produces a characteristic banding pattern of six bands membranes to an image plate. The mean lengths of TRFs were corresponding to the first to sixth TRAP product. Using analyzed with a Phosphorimager (Molecular Dynamics, SunImageQuant software (Molecular Dynamics, Sunnydale, CA, nyvale, CA, USA). Mean TRF lengths were defined as ⌺(OD i USA), we quantified the signal intensity by determining the − L i )/⌺ (OD i ) where OD i is the densitometer output and L i is radioactivity of each repeat ladder corrected for the backthe length of DNA in position i . 5, 19 Sums were calculated over ground, and by expressing the total count per reaction (TPG) the range of 2-23 kbp.
Telomere peak values were measured using the formula:
by estimating the band size corresponding to the point with the highest absorbence. 19 Differences in TRF peak values were TPG = (T − B)/(CT) (R8 − B)/CR8) × 100 defined as a divergence of at least 2 kbp.
The abbreviations used are: T, radioactive count from telomerase bands from the test extract; B, counts from negative conResponse criteria trol (background); R8, counts from R8 (0.1 amol); CT, counts from the internal control TSNT (0.01 amol) of the test extract, In acute leukemias, response was evaluated using standard morphological criteria in BM aspirates and biopsies. Cytoand CR8, counts from TSNT (0.01 amol) of the R8 (quantitation standard) (0.1 amol). The final quantitation was genetic and immunophenotypic analyses were also performed. 1,2,37-40 Complete response (CR) was defined when BM expressed as TPG (total product generated). One unit of TPG was defined as 0.001 amol, or 600 molecules, of TS primers blasts were Ͻ5%. In ST, the response was evaluated using WHO criteria: CR was defined as the disappearance of all ALL-L2, and one patient was diagnosed as AML-M1 according to the FAB classification. Immunophenotypically, 11 ALL were measurable tumor lesions for at least 4 weeks, partial response (PR) as a reduction of at least 50% in the sum of the products defined as early pre-B leukemias, two as mixed lineage and two as T cell lineage. At diagnosis, the median white blood of the perpendicular diameter of all lesions and progressive disease (PD) if an increase in tumor size of у25%, or occurcount (WBC) in acute leukemia patients was 10 050 cells/l (range 1200-716 000). Three ALL patients had high-risk leukerences of new tumor sites were detected. mia with extensive leukemic burden (WBC Ͼ100 000/l). Twelve out of 15 patients were characterized as standard-risk ALL. A normal karyotype was present in 15/16, in only one
Calculation of number of cell divisions ALL patient numerical and structural chromosome abnormalities were found (46,XY,t(2p;11p) [2] , del (7p) [7] ,−9 [7] ,−13 [7] , An evaluation of the number of population doublings (PD) in leukemia and tumor specimens, based on differences of mean +2mar [7] [cp],46,XY). The median time to achieve a complete response in acute leukemia patients was 28 days (range, 7-and peak TRF length in leukemia and tumor block specimens, and in cell controls (such as granulocyte fractions) was per-44). At diagnosis, both BM and PB specimens were available in 12/16 leukemia patients, in the remaining four, only PB formed. The following formula was applied: Mean or peak TRF at diagnosis in granulocytes − TRF leukemia/ST specimen :0.05 = number was analyzed. Two ST patients had metastatic disease: one metastatic of PD. In order to establish the effect of repeated chemotherapy cycles on telomere shortening, we used the formula:
Ewing's sarcoma patient with bone and BM metastases and a stage IV Wilms' tumor patient with pulmonary metastases. In Mean or peak TRF (kbp) at diagnosis − TRF after therapy . For all calculations, a loss of 50 bp per PD was used since telomeric DNA these two patients, BM and PB specimens were obtained at diagnosis. Among 25 pediatric patients (15 ALL, one AML, loss in somatic tissue has been reported at a rate of 35-100 bp. 11, 13 nine ST), each was examined at diagnosis, with at least one follow-up specimen obtained in 23 out of 25 after induction of chemotherapy. On average three follow-up specimens per patient were collected.
Statistics
The median number of chemotherapy cycles in all pediatric patients was five (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] ( Figure 1a) . In all donors, median telomerase activity was 1.86 TPG, and was less than one TPG in BM and PB specimens in increased telomerase as activity higher than expected relative
Peripheral blood (PB) 65
to age (ie Ͼmean − 2 × s.d.).
Bone marrow (BM) 31
At diagnosis, high telomerase activity (defined as Ͼ50 TPG)
was found in BM and PB MNCs from acute leukemia patients (100%) ( (10/12) and moderate activity in 16% (2/12). At diagnosis, BM revealed a four-fold increased telomerase activity (range 1.1-had localized disease (7/9), only weak telomerase activity was found (Figure 2b ). This was 10-to 15-fold lower compared 35) compared to PB MNCs (P = 0.005), correlating with higher leukemic burden in marrow specimens (mean leukemic BM to diagnostic leukemia and tumor block specimens (P Ͻ 0.05) ( Table 2 ). The two ST patients with systemic disease (one infiltration: 78.8% vs 30% in PB specimens). PB specimens in acute leukemia had high telomerase activity in 25% (4/16) Ewing's sarcoma, one Wilms' tumor) had increased telomerase activity in BM and PB MNCs (BM, 24.7 TPG; PB, 11.1 and moderate activity in 75% of patients (12/16). Of note was that leukemia patients with moderate telomerase activity in TPG) ( Table 2 ). After induction therapy in ST patients, telomerase activity in MNCs decreased even further, revealing levels PB specimens were those with lower peripheral leukemic blast counts and with lower WBC counts at diagnosis (median comparable to very low telomerase activity in CB, PB and BM MNCs from healthy donors (1.86 TPG) ( Table 2) . Differences 5800/l, range 1200-34 900). In high-risk ALL patients (3/16; median WBC: 336 500/l, range: 109 100-716 000), telomerof telomerase activity between diagnostic and follow-up PB specimens in ST patients and healthy donors were insignifiase activity in blood and marrow specimens was 3.1-fold increased (89.9 TPG) as compared to standard-risk ALL cant (P = 0.1) (Figure 2b ). Alkaline phosphatase was found to be present in all pedi-(12/12; WBC, 5800/l, range 1200-34 900) with 24 TPG. One patient with L2 (216 TPG) and one with cytogenetic atric patients, in solid tumor biopsies and healthy donors. abnormalities (72 TPG) had increased telomerase activity, as well as elevated WBCs at diagnosis of 34 900/l and 716 000/l, respectively. There was no difference in telomerTelomere length analysis (TRF analysis) ase activity in early pre-B, mixed and T cell lineage ALL. The patient with AML M1 displayed telomerase activity of 25 TPG From healthy donor specimens, we determined that telomere length decline is related to aging according to in the diagnostic BM specimen (WBC 30 000 /l). Telomerase activity in diagnostic AML and ALL specimens was compara-TL = 10.34 − 0.057 × A (r = −0.6, P Ͻ 0.05; where TL is the TRF in kbp and A is age in years) (Figure 1b ). According to ble (Figure 2b ). Granulocytes as opposed to MNCs lacked telomerase activity in all groups (Table 2) .
our calculations, a 30-year-old healthy donor would be predicted to have telomeres of 8.6 kbp, whereas an 80-year-old In diagnostic acute leukemia specimens, telomerase activity was significantly enhanced compared to healthy donors of 5.8 kbp, resulting in a telomere loss of 2.8 kbp within a 50-year period and corresponding to 56 bp per year. Acute (P Ͻ 0.05). After induction chemotherapy, telomerase activity decreased in leukemia specimens (25-fold) (P Ͻ 0.01), and leukemia patients with shortened telomeres were defined as such when TRF lengths were shorter than expected relative to was low (Ͻ5 TPG) or undetectable with the attainment of complete remission, during consolidation and maintenance their age (ie Ͻmean − 2 × s.d.). Average telomeres in childhood PB MNCs were long. Howchemotherapy, both in marrow and blood. Thus, with the attainment of CR, acute leukemia patients showed very low ever, since Southern blot TRF analysis consists of a smear of cellular DNA from malignant and normal cells, mean and or no telomerase activity (Figure 2a and b) .
In ST block specimens from pediatric patients, high telomerpeak TRF values were analyzed in this study, and are given in Tables 3, 4 and 5. In the leukemic phase at diagnosis, 100% ase was detected which was comparable to diagnostic BM and PB in leukemic samples (P = 0.6) (Table 2, Figure 2b) . In of BM and PB specimens with verified blast cells revealed two distinct peak TRF values of more than at least 2 kbp difference contrast, in BM and PB MNCs from ST patients most of whom (a) Depicts telomerase activity in peripheral blood specimens of all leukemia and solid tumor patients. Telomerase activity decreased from diagnosis (D) to follow-up (F) in all patients. The decrease in telomerase activity was significant after induction chemotherapy and response to treatment (shown here for median telomerase activity determined from all PB specimens in leukemia and solid tumor patients). (b) Displays a representative TRAP gel. Lane 1-6 shows the reduction of telomerase activity from diagnosis (D) to follow-up (F) in a representative ALL patient. Lanes 7 + 8 and 9 + 10 demonstrate telomerase activity at diagnosis and after induction chemotherapy in follow-up specimens in an ALL and AML patient, respectively. Both leukemia patients had high telomerase activity at diagnosis and low or no telomerase with the attainment of CR. Lanes 11-14 show telomerase activity in ST block specimens. Telomerase activity in PB specimens of solid tumor patients was lower than in ST blocks (lanes 16-18), except for those ST patients with systemic (stage IV) disease (lane 15, Ewing sarcoma patient with bone and BM metastases). In PB MNCs from healthy donors (HD), borderline or no telomerase activity was found as shown in lanes 19-21. ‫,ء‬ marks significant changes (P Ͻ 0.05). f TA in leukemia and ST tissue specimens was significantly higher (P Ͻ 0.05) than in peripheral blood specimens from ST patients with localized disease and from healthy donors (HD). g TA in PB from ST patients with localized disease and from HD was low. TA, both in PB from ST patients and from HD, differed insignificantly. BM = bone marrow, PB = peripheral blood, CB = cord blood. ( Table 3 ). The larger one (in kbp; peak 1) corresponded in size shorter than the mean TRF value of 10.5 kbp in acute leukemia specimens (Table 3) . Since mean values comprised both with the granulocyte fraction used in each patient as a control, and the smaller peak (peak 2) most likely representing the leulonger (normal cells) and shorter (leukemic clone) peaks, peak values reflected telomere lengths of leukemic cells better than kemic blasts. This suggests that two distinct populations of cells in acute leukemia specimens were detected: a normal mean TRF values (Table 3) . Despite the malignant cell burden in leukemia and ST cell population as the longer peak and a shorter peak that contained leukemic cells which had progressively shortened patients with systemic disease, mean TRFs in all pediatric patients were longer with 10.9 ± 2 kbp (peak 11.9 ± 1.3 kbp) after extensive proliferation, presumably prior to telomerase upregulation to levels capable of stabilizing the telomeres of (Figure 3a ) compared to adult PB (n = 32; 7.4 ± 0.9 kbp) and adult BM MNCs (n = 8; 7.75 ± 0.7 kbp) (P Ͻ 0.001). Mean the leukemic clone. The smaller peak of 7.8 kbp was much TRFs in pediatric patients (10.9 ± 2 kbp) were similar to CB Standard chemotherapy generally achieves a 2-to 3-log reduction in the total tumor burden, and results in minimal specimens (11 ± 1 kbp). Granulocytes in leukemia patients had longer mean and peak TRF values at diagnosis, due to the residual disease, below the level of clinical detection. For this reason, acute leukemias are intriguing to study in order to absence of the malignant clone within this fraction (P Ͻ 0.05) ( Table 4 , Figure 3a and b). In diagnostic BM MNC specimens learn about potential changes before and after induction of remission. This is especially true since molecular alterations in leukemia, mean and peak TRFs were significantly shorter compared to PB specimens with 1.4 ± 0.5 kbp and associated with genetic abnormalities have provided insights into mechanisms through which a disease is generated and 3.8 ± 1.1 kbp, respectively (Figure 3a and b) . After repetitive chemotherapy cycles, the telomere loss was more pronounced directions in which novel therapies can be developed. Evidence from previous studies suggest that the pathogenesis of in granulocytes, as compared to MNCs with 1.8 kbp (1.7 kbp in ALL; 1.9 kbp in ST) vs 1 kbp, respectively (P = 0.014) cancer proceeds by sequential steps from normal to malignancy, associated with molecular changes involving genes (Table 5 , Figure 3a and b). Telomeres in leukemic MNCs gained on average 2.2 kbp after induction chemotherapy, but such as RAS, p53, mdm-overexpression or bcr-abl.
1,2,45
Telomerase, the enzyme that prevents telomere shortening, decreased 1 kbp with the continuation of chemotherapy treatment (Figure 3a and b) . The overall increase ranged from 0.53 has recently received much attention due to its involvement in most tumor types, including childhood leukemia and solid to 1.56 kbp (P Ͻ 0.05).
In the ST group, only two patients with systemic disease neoplasias. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [46] [47] [48] [49] Previous studies in childhood and adult leukemia have suggested that telomerase activity and short tel-(one Ewing's sarcoma, one Wilms' tumor) revealed two peak TRF values at diagnosis (peak 1: 11.7 kbp, peak 2: 7.8 kbp)
omeres may correlate with disease progression and cytogenetic abnormalities. 23, 24, 49 However, few studies have cor- (Table 3) . With attainment of remission in ALL, AML and ST patients, the lower TRF peak was lost. Average telomere related telomerase activity and telomere length analysis with clinical outcome, prognosis and with response to treatlength in tumor blocks was 7.7 kbp, which correlated with lower peak values observed in marrow and blood specimens ment. 15, 17 Moreover, the assessment of telomerase in blood and marrow products is somewhat challenging, since recent (Table 3) . Mean and peak telomere length in PB granulocytes and MNCs of ST patients, were insignificantly different at diagstudies have demonstrated low telomerase activity in primitive hematopoietic cells. [6] [7] [8] [9] Telomerase activity may also be influnosis (Table 4) . After chemotherapy, telomere loss in PB MNCs in ST patients was on average 1.2 kbp (P Ͻ 0.05) enced by parameters other than clinicopathological features, such as sensitivity of the assay, telomerase inhibitors, viability (Table 5 , Figure 3a and b) . The changes in TRF over baseline ranged from 0.8 to 2.55 kbp. Two ST patients received highof the tissue or different tumor cell infiltration. 18, [50] [51] [52] In this study, we used the highly sensitive TRAP assay that enables dose chemotherapy with ABMT in one, and PBSCT in the other. Both demonstrated a TRF loss that was more proestimation of activity in a quantitative manner. Potential telomerase inhibitors were excluded by analyzing protein degranounced compared to standard chemotherapy (SC) of 1.7 kbp (SC: 1.2 kbp) in MNCs and of 2.6 kbp (SC: 1.8 kbp) in granulodation by alkaline phosphatase and by using an internal PCR control standard. We sought to determine: (1) whether telocytes (Figure 3b) .
In order to assess the reproducibility of the TRF analysis, PB merase and telomere length measurements in leukemia as opposed to ST and healthy donor specimens differ at diagand BM specimens (n = 30) were analyzed on repetitive TRF Southern blots, revealing an average variance of 4.3% nosis, during and after therapy; (2) whether potential differences between blood and marrow exist; (3) whether distinct (0.4 kbp).
cell fractions, such as MNC and granulocytes, show significant differences during chemotherapy treatment; (4) whether there are potential differences between pediatric patients and Discussion healthy donors; and (5) whether telomerase and telomere length analysis may serve as prognostic molecular markers Over the past few decades, considerable advances in the treatment of pediatric leukemia, especially in acute lymphocytic in leukemia.
In agreement with previous reports, 6, 8, 24 we found high teloleukemia (ALL) have been made. Treatment with conventional chemotherapy regimens in ALL results in impressive CR rates merase activity in diagnostic leukemia and pediatric tumor specimens. However, very high telomerase activity as of 90-100% and long-term remission rates of Ͼ70%. 11 (F) ). In leukemia, after induction chemotherapy, telomeres in MNCs gained on average 2.2 kbp, but decreased 1 kbp with the continuation of chemotherapy treatment (lanes 7-9). In ST patients, telomere loss in PB MNCs was 1.2 kbp after chemotherapy (lanes 10 + 11). (b) shows a representative Southern blot analysis in pediatric leukemia and solid tumor specimens. Lanes 1 + 2 depict MNCs (1) and granulocytes (2) in a representative ALL patient at diagnosis (D). In the leukemic phase, BM and PB specimens revealed two distinct peak TRF values of more than at least 2 kbp difference (lanes 1, 3, 6 ). The larger one (in kbp) corresponded closely in size to the granulocyte fraction (lanes 2, 5) used in each patient as a control, and the smaller peak most likely representing the tumor (lanes 1, 3, 4, 6 ). BM specimens in leukemia had shorter mean TRF values, most likely due to the increased leukemic burden (lane 3) compared to PB specimens (lane 4). Lanes 7-13 demonstrate the initial increase in telomeric length after induction chemotherapy in leukemia with loss of the malignant clone. However, this was decreasing with the continuation of chemotherapy treatment (lanes 14-16). Two ST patients received high-dose chemotherapy. The impressive telomeric loss after intensified chemotherapy is shown in lanes 17-20 (17, diagnosis (D); 18-20, follow-up (F)). ‫ء‬ marks significant changes (P Ͻ 0.05).
observed in immortal tumor cell lines was uncommon in leuwith age in accordance with published literature. 45 Since MNCs in normal donors are mainly composed of lymphocytes kemia. 6, 9, [14] [15] [16] [17] [18] Telomerase activity decreased significantly with the attainment of CR in ALL and AML. Low to borderline telowhich like primitive hematopoietic progenitor cells express weak telomerase activity, 10 ,53-55 lymphocytes may most likely merase activity was detected in blood specimens of ST patients and healthy donors, in the latter group decreasing have accounted for low levels of telomerase activity found in 22 donor specimens. Granulocytes used as a control cell fraction MNCs and granulocytes, especially in adults, escalated with high-dose chemotherapy regimens, may lead to unknown revealed no telomerase activity in all groups. Our results demonstrate that elevated telomerase was a frequent event in long-term side-effects when these patients become older. In pediatric leukemias after successful chemotherapy and childhood leukemia, especially in marrow specimens, in patients with elevated WBC, with chromosomal abnormalities achievement of complete remission, there is a dramatic agerelated increase in myelodysplastic syndrome (MDS), and the and in high-risk ALL patients. This suggests that telomerase plays an important role in the process of multi-stage leukeincreased incidence of MDS and secondary leukemias is associated with high-dose chemotherapy, particularly with automogenesis, and that telomerase activation eventually results in stabilization or elongation of telomeres, subsequent logous and allogeneic transplantation. MDS/secondary leukemia is frequently associated with chromosome loss immortalization, increased leukemic potential and disease progression.
(monosomy 7), chromosome deletions and translocations. Therefore, long telomeres may be important to chromosomal Telomere length measurements have been used as a marker for cell proliferation and population doublings alignment and stabilization in mitosis, and short telomeres may predispose to cytogenetic abnormalities. From our (PD). 3, 12, 19, 25, [56] [57] [58] In this study, we analyzed mean and peak values, since the acquisition of mean TRF values alone may results, one can hypothesize that telomere length shortening reflects a possible effect on all cells including somatic cells be inaccurate. In acute leukemia, most BM and PB specimens allowed the detection of two peaks: the longer corresponding which would then lead to premature aging, unless telomeres can recover, elongate and potentially gain their initial length to normal cells, correlating with telomeres of granulocyte controls, and the shorter peak corresponding to the leukemic after discontinuation of chemotherapy. Recently, a study of late hematopoietic reconstitution at the level of committed clone. This was supported by our evaluation of ST block specimens which demonstrated TRF values corresponding to and early progenitor cells after allogeneic bone marrow transplantation demonstrated a significantly reduced number of peak TRFs observed in those ST patients with systemic disease and marrow involvement. Thus, the analysis of peak values early progenitors despite normal numbers of committed cells and normal peripheral blood counts. 61 This suggests a permaallowed the detection of tumor cells with short telomeres.
We found considerably longer telomeres in pediatric nent reduction of the stem cell reservoir, the loss of selfrenewal property after strong proliferative stress, and possibly patients than in BM and PB specimens of adult healthy donors. High telomerase and telomere shortening in leukemia a telomeric DNA decline after high-dose chemotherapy. 61 Therefore, of great interest for future studies are long-term and ST specimens supports the concept that telomerase was turned on late in tumorigenesis after a high number of popueffects on telomere dynamics after chemotherapy and highdose protocols. lation doublings (PDs) has occurred.
14,16 Extensive proliferation in ALL and AML was confirmed by calculating cell According to our calculations from CB, PB and BM specimens in healthy donors, we found a telomere loss of 56 per doublings. Telomeres of granulocytes were used as the control cell population for normal TRF length, and lower TRF peaks year. Previous results on telomere loss in various somatic tissues range from 20-200 bp per population doubling (PD) were consistent with leukemic cells. Average PDs in leukemia were 82.4 (assuming a base pair loss of 50 per cell and of 40 bp per year in human fibroblasts. 9, 14, 57 However, under extensive proliferative stress in cytokine supported ex division). 11, 19 In adult AML and childhood leukemia, telomere shortening has been observed, with length being restored in vivo expansion cultures, hematopoietic progenitors lose 80 to Ͼ200 bp per PD. 9 This apparent difference in telomere base the remission state. 23, 24, 46, 59, 60 Our results confirm this observation demonstrating that telomeres gained on average pair shortening may in part be explained due to only transient telomerase expression. In primitive hematopoietic cells, how-2.2 kbp after induction chemotherapy in leukemia. We are the first, however, to show that telomeres were shortening in norever, telomerase activity proved insufficient to completely prevent telomere shortening. 9 Therefore, based on our calcumal hematopoietic cells as a result of chemotherapy treatment, both in ST, ALL and AML patients. Although telomere lation of 56 bp loss per year, one would predict the following theoretical calculation: assuming a telomere length of 11 kbp shortening was detected in MNCs, chemotherapy with repeated cycles of hematopoietic regeneration, induced a telat birth, with cells reaching their Hayflick limit at 3 kbp, telomere length would be exhausted and reach senescence after omere loss that was most pronounced in granulocytes. This suggests that the myelosuppressive effect of repeated chemoa life span of 125 years. If, however, prolonged chemotherapy and high-dose protocols induced a telomere loss of 1-2 kbp therapy has a greater effect on the myeloid than on the lymphoid lineage, and that the effects of repetitive myelosuppressive and length was not restored after the end of treatment, the Hayflick limit in these patients would be reached 18-36 chemotherapy cycles can be monitored. Repeated chemotherapy imposes repeated waves of proliferative regeneration. years earlier.
In summary, we found that telomerase activity in acute leuIn a transplant only approximately 1% of the total stem cell pool is transplanted, thus considerable proliferation is kemia was commonly acquired, and that increased telomerase activity correlated with the leukemic burden in BM specimens required to regenerate the hematopoietic system. Our results demonstrate that utilization of TRF analysis in leukemia may and high-risk patients. At diagnosis, telomerase was consistently and highly upregulated in leukemia, decreased with be an important tool not only for monitoring response to treatment, but also for monitoring TRF loss induced by prolonged therapy induction, and correlated with remission. A 10-fold weaker telomerase activity was detected in healthy donors myelosuppressive chemotherapy with extensive regeneration. Prolonged chemotherapy treatment in our patients when it and in blood or marrow of ST patients, showing elevated telomerase levels only in those patients with systemic disease. exceeded five cycles of chemotherapy and high-dose intensification protocols, both of which required hematopoietic Likewise, physiologically regenerating somatic tissue such as human epithelial cells, lymphocytes or primitive hematoporegeneration, induced a telomere loss of 1-2 kbp. This did not lead to the approach of the Hayflick limit in MNCs and graietic cells have demonstrated low levels of activity. 9, 62, 63 This suggests that weak telomerase activity may play a role in the nulocytes in pediatric patients, since telomeres in these patients are sufficiently long. However, a loss of 1-2 kbp in regenerative capacity of somatic stem cells compared to the
